Anti-mitochondrial antibodies, the characteristic markers of primary biliary cirrhosis, have been detected in most patients with this disease. However, the prevalence of these antibodies in inflammatory myopathies and their clinical and histopathological significance has not been determined. Sera from 212 consecutive patients with inflammatory myopathies were screened for anti-mitochondrial antibodies by enzyme-linked immunosorbent assay. The clinical and histopathological features of anti-mitochondrial antibody-positive patients were analysed and statistically compared with those of anti-mitochondrial antibody-negative patients. Twenty-four patients positive for anti-mitochondrial antibodies (seven patients with and 17 patients without primary biliary cirrhosis) were identified (11.3%). Thirteen patients had a clinically chronic disease course of >12 months before their diagnosis at hospitals. Six of these 13 patients (four asymptomatic patients with increased creatine kinase levels and two patients with arrhythmia) had not been aware of muscle weakness, but all 13 patients had muscle atrophy at initial presentation. As complications, eight patients had cardiac involvement including arrhythmias (five patients with supraventricular tachycardia; two with ventricular tachycardia; and one patient with atrioventricular block), six patients had moderately decreased ejection fraction and six patients had decreased vital capacity, two of whom required respiratory support. Regarding muscle histopathological findings, in addition to inflammation, 13 patients had chronic myopathic changes and six had granulomatous lesions. Statistical analysis showed that the clinical features of a chronic disease course, cardiac involvement and muscle atrophy, and the histopathological features of chronic myopathic changes and granulomatous inflammation, were significantly more frequently observed in patients with anti-mitochondrial antibody-positive inflammatory myopathy than in patients who were negative for anti-mitochondrial antibodies. Except for cardiac involvement, which is more frequently observed in patients with primary biliary cirrhosis, no significant differences in clinical or histopathological features were found between patients with or without primary biliary cirrhosis. Our study revealed that inflammatory myopathies associated with anti-mitochondrial antibodies were frequently found in patients with the clinical features of a chronic disease course, muscle atrophy and cardiopulmonary involvement, and the characteristic histopathological feature of granulomatous inflammation. Our study suggests that inflammatory myopathies associated with anti-mitochondrial antibodies form a characteristic subgroup.
CAM includes clinicohistopathologically heterogeneous disease entities. Among CAM entities, anti-TIF1-γ-Ab(+) CAM has characteristically shown a close temporal association with cancer detection and the histopathologic findings of dC5b-9 and VFs, and CAM with NAM is a subset of anti-TIF1-γ-Ab(-) CAM.
Objective:To show cancer association is a risk factor other than statin exposure for anti-3-hydroxy-3-methylglutaryl coenzyme A reductase autoantibody-positive (anti-HMGCR Ab+) myopathy.Methods:We analyzed the clinical features and courses of 33 patients (23 female and 10 male) with anti-HMGCR Ab+ myopathy among 621 consecutive patients with idiopathic inflammatory myopathies.Results:Among the 33 patients, 7 (21%) were statin-exposed and 26 were statin-naive. In relation with cancer, there were 12 patients (statin-exposed, n = 4) with cancers detected within 3 years of myopathy diagnosis (cancer association), 3 patients (all statin-naive) with cancers detected more than 3 years before myopathy diagnosis (cancer history), 10 cancer-free patients followed up for more than 3 years (all statin-naive), and 8 patients without cancer detection but followed up for less than 3 years (statin-exposed, n = 3). Therefore, 12 patients with cancer association (36%) formed a larger group than that of 7 statin-exposed patients (21%). Among 12 patients with cancer association, 92% had cancer detection within 1 year of myopathy diagnosis (after 1.3 years in the remaining patient), 83% had advanced cancers, and 75% died of cancers within 2.7 years. Of interest, 1 patient with cancer history had sustained increase in creatine kinase level over 12 years from cancer removal to the development of weakness.Conclusions:Patients with cancer association formed a large group with poor prognosis in our series of patients with anti-HMGCR Ab+ myopathy. The close synchronous occurrence of cancers and myopathies suggested that cancer association is one of the risk factors for developing anti-HMGCR Ab+ myopathy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.